Light-Activatable Theranostic Agents for Image-Monitored Controlled Drug Delivery

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Materials Science

Background:

• Controlled drug delivery systems are crucial for therapeutic efficacy and minimizing side effects.
• Light-activated drug release offers spatiotemporal control over medication delivery.
• Nanoparticle-based systems provide platforms for targeted and efficient drug encapsulation.

Purpose of the Study:

• To develop and characterize a novel light-activatable nanodroplet system for controlled drug release.
• To investigate the mechanism of drug release triggered by plasmonic photothermal heating.
• To evaluate the stability, noninvasive monitoring, and therapeutic potential of the nanodroplets.

Main Methods:

• Fabrication of nanodroplets coated with gold nanorods for plasmonic photothermal conversion.
• Encapsulation of therapeutic agents within the nanodroplets.
• Light irradiation to induce phase transition and drug release.
• Ultrasound imaging for quantitative analysis of drug release.
• In vitro cytotoxicity assays and ex vivo studies for therapeutic evaluation.

Main Results:

• Nanodroplets demonstrated stability at 4 °C for over 3 months without aggregation or dissolution.
• Light irradiation induced vaporization of nanodroplets, leading to controlled drug release.
• Ultrasound imaging provided noninvasive quantification of drug release.
• In vitro studies confirmed light-dependent cell death upon drug release.
• Ex vivo studies indicated potential for treating posterior eye diseases.

Conclusions:

• Gold-nanorod-coated, light-activatable nanodroplets represent a promising platform for controlled drug delivery.
• The system allows for dosage monitoring through noninvasive ultrasound imaging.
• This technology holds potential for targeted therapies, particularly in ophthalmology.